Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 8/20 | 0.33 |
| ▸ | RXRB | P28702 | 3/20 | 0.33 |
| ▸ | RARB | P10826 | 7/20 | 0.32 |
| ▸ | RARG | P13631 | 7/20 | 0.32 |
| ▸ | RARA | P10276 | 6/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406406 | 0.87 | RXRA (0.36) | RXRARXRBRARBRARGRARA | |
| SCHEMBL1406482 | 0.79 | RARB (0.50) | RXRARXRBRARBRARGRARA | |
| SCHEMBL5044048 | 0.78 | NR4A2 (0.35) | RXRARXRBRXRG | |
| SCHEMBL1406400 | 0.76 | CYP26A1 (0.42) | RXRARXRBRARBRARGRARA | |
| SCHEMBL1406519 | 0.76 | XDH (0.40) | AKR1C2RXRARXRBRARBRARG | |
| SCHEMBL1406628 | 0.73 | RXRA (0.43) | RXRARXRBRARBRARGRARA | |
| SCHEMBL6157965 | 0.72 | RXRA (0.52) | RXRARXRBRARBRARGRARA | |
| SCHEMBL6157083 | 0.72 | RXRA (0.52) | RXRARXRBRARBRARGRARA | |
| SCHEMBL1406577 | 0.72 | RXRA (0.36) | RXRARXRBRARBRARGRARA | |
| SCHEMBL1406775 | 0.70 | RARB (0.48) | AKR1C2RXRARXRBRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-7468457-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1513793-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101928-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | AKR1C3 1403/4885AKR1C2 1063/4885RXRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.